---
title: "EW: Q2 sales up 13.6% to $1.74B; guidance raised on strong TAVR/TMTT growth and robust cash position"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293663550.md"
description: "Q2 sales rose 13.6% to $1.74B, with double-digit growth in TAVR and TMTT segments and adjusted EPS up to $0.78. Full-year sales and EPS guidance were raised, supported by strong global adoption and favorable clinical data. Cash stood at $2.9B with $1.5B in share repurchase authorization.Original document: Edwards Lifesciences Corporation [EW] SEC 8-K Current Report — Jul. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-23T20:28:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293663550.md)
  - [en](https://longbridge.com/en/news/293663550.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293663550.md)
generator: "portal-rs"
---

# EW: Q2 sales up 13.6% to $1.74B; guidance raised on strong TAVR/TMTT growth and robust cash position

Q2 sales rose 13.6% to $1.74B, with double-digit growth in TAVR and TMTT segments and adjusted EPS up to $0.78. Full-year sales and EPS guidance were raised, supported by strong global adoption and favorable clinical data. Cash stood at $2.9B with $1.5B in share repurchase authorization.

Original document: Edwards Lifesciences Corporation \[EW\] SEC 8-K Current Report — Jul. 23 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [EW.US](https://longbridge.com/en/quote/EW.US.md)

## Related News & Research

- [Here’s How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years](https://longbridge.com/en/news/296380036.md)
- [Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says](https://longbridge.com/en/news/293778081.md)
- [Humacyte says Phase 3 V012 trial shows ATEV extends catheter-free dialysis time in women](https://longbridge.com/en/news/296784335.md)
- [BioCardia: Advancing Regulatory Momentum in Helix Catheter and CardiAMP HF Programs Supports Buy Rating and Unchanged $25 Price Target](https://longbridge.com/en/news/296809944.md)
- [Elevation Point Wealth Partners LLC Invests $1.66 Million in Edwards Lifesciences Corporation $EW](https://longbridge.com/en/news/296755573.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**